University of Surrey

Test tubes in the lab Research in the ATI Dance Research

Urinary melatonin levels, sleep disruption, and risk of prostate cancer in elderly men

Sigurdardottir, L.G., Markt, S.C., Rider, J.R., Haneuse, S., Fall, K., Schernhammer, E.S., Tamimi, R.M., Flynn-Evans, E., Batista, J.L., Launer, L. , Harris, T., Aspelund, T., Stampfer, M.J., Gudnason, V., Czeisler, C.A., Lockley, S.W., Valdimarsdottir, U.A. and Mucci, L.A. (2015) Urinary melatonin levels, sleep disruption, and risk of prostate cancer in elderly men European Urology, 67 (2). pp. 191-194.

Full text not available from this repository.

Abstract

Melatonin has anticarcinogenic properties in experimental models. We undertook a case-cohort study of 928 Icelandic men without prostate cancer (PCa) nested within the Age, Gene/Environment Susceptibility (AGES)-Reykjavik cohort to investigate the prospective association between first morning-void urinary 6-sulfatoxymelatonin (aMT6s) levels and the subsequent risk for PCa, under the hypothesis that men with lower aMT6s levels have an increased risk for advanced PCa. We used weighted Cox proportional hazards models to assess the association between first morning-void aMT6s levels and PCa risk, adjusting for potential confounders. A total of 111 men were diagnosed with incident PCa, including 24 with advanced disease. Men who reported sleep problems at baseline had lower morning aMT6s levels compared with those who reported no sleep problems. Men with morning aMT6s levels below the median had a fourfold statistically significant increased risk for advanced disease compared with men with levels above the median (hazard ratio: 4.04; 95% confidence interval, 1.26-12.98). These results require replication in larger prospective studies with longer follow-up. Patient summary In this report, we evaluated the prospective association between urinary aMT6s levels and risk of PCa in an Icelandic population. We found that lower levels of aMT6s were associated with an increased risk for advanced PCa. © 2014 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Item Type: Article
Authors :
NameEmailORCID
Sigurdardottir, L.G.
Markt, S.C.
Rider, J.R.
Haneuse, S.
Fall, K.
Schernhammer, E.S.
Tamimi, R.M.
Flynn-Evans, E.
Batista, J.L.
Launer, L.
Harris, T.
Aspelund, T.
Stampfer, M.J.
Gudnason, V.
Czeisler, C.A.
Lockley, S.W.s.lockley@surrey.ac.uk
Valdimarsdottir, U.A.
Mucci, L.A.
Date : 2015
DOI : 10.1016/j.eururo.2014.07.008
Uncontrolled Keywords : Circadian rhythm, Melatonin levels, Prostate cancer, 6 hydroxymelatonin o sulfate, beta adrenergic receptor blocking agent, creatinine, melatonin, 6-sulfatoxymelatonin, biological marker, melatonin, advanced cancer, aged, Article, cancer risk, case study, cohort analysis, genetic association, genotype environment interaction, high risk population, hormone urine level, human, Icelander, incidental finding, major clinical study, male, micturition, priority journal, prostate cancer, risk assessment, sleep disorder, age, analogs and derivatives, down regulation, Iceland, incidence, pathophysiology, proportional hazards model, Prostatic Neoplasms, risk factor, sleep, Sleep Wake Disorders, time factor, urine, Age Factors, Biomarkers, Down-Regulation, Humans, Iceland, Incidence, Male, Melatonin, Proportional Hazards Models, Prostatic Neoplasms, Risk Assessment, Risk Factors, Sleep, Sleep Wake Disorders, Time Factors
Depositing User : Clive Harris
Date Deposited : 17 Jun 2020 01:16
Last Modified : 17 Jun 2020 01:16
URI: http://epubs.surrey.ac.uk/id/eprint/857870

Actions (login required)

View Item View Item

Downloads

Downloads per month over past year


Information about this web site

© The University of Surrey, Guildford, Surrey, GU2 7XH, United Kingdom.
+44 (0)1483 300800